Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation - 08/08/11
Reprint requests: Sylvia Hsu, MD, Professor, Department of Dermatology, Baylor College of Medicine, 6620 Main St, Suite 1425, Houston, TX 77030.Abstract |
Background |
The scalp is the most commonly affected part of the body in patients with psoriasis. Signs and symptoms of scalp psoriasis vary significantly for individual patients.
Objective |
A task force of the National Psoriasis Foundation was convened to evaluate treatment options. Our aim was to achieve a consensus for scalp psoriasis therapy.
Methods |
Reports in the medical literature were reviewed regarding scalp psoriasis therapy.
Limitations |
There is a paucity of evidence-based and double-blind studies in the treatment of scalp psoriasis particularly for long-term therapy. Many of the studies in scalp psoriasis were designed to attain Food and Drug Administration approval for a medication and not to provide treatment guidance.
Conclusions |
The recommended short-term or intermittent therapy for scalp psoriasis is topical corticosteroids. The primary alternatives are topical retinoids, vitamin D analogues, and salicylic acid. Combination therapy has many advantages. The choice of an appropriate vehicle is crucial to increase patient compliance. While scalp psoriasis can often be adequately treated with topical therapy, recalcitrant disease may require more aggressive approaches, including systemic agents.
Le texte complet de cet article est disponible en PDF.Abbreviations used : MeSH, PASI, PSSI
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Van Voorhees has been a consultant investigator or speaker for Abbott, Amgen, Astellas, Centocor, Genentech, Incyte, Connetics, Warner Chilcott, Photomedix, Roche, and Synta; she has a significant conflict of interest with Merck. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott. He has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Korman has been a consultant for Abbott, Astellas, Centocor, and Genentech; he has also been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Ms Young has been a consultant or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Foundation. The Foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Dr Kalb has been an investigator and consultant for Abbott, Amgen, Centocor, Astellas, Warner-Chilcott, Stiefel, and Genentech. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech; she has been a clinical investigator for Amgen and Centocor. Dr Chan has no conflicts of interest to declare. |
Vol 60 - N° 6
P. 962-971 - juin 2009 Retour au numéro
Article précédent
- Store-and-forward teledermatology versus in-person visits: A comparison in pediatric teledermatology clinic
- Viday A. Heffner, Valerie B. Lyon, David C. Brousseau, Kristin E. Holland, Kenneth Yen
- Change of Name of Self-Assessment Examination
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?